Carl brings substantial experience in late-stage drug development in orphan diseases having served in senior roles in both large international pharma companies such as Sanofi, Genzyme and Lundbeck as well as in the Swedish biotech company Wilson Therapeutics as CMO. Carl is a Medical Doctor (M.D.) and holds a PhD degree from University of Linköping.
“We are very pleased with the appointment of Carl Bjartmar as CMO. Carl has a long and solid track record in late-stage orphan drug development and has among other things been a key member of the management team in Wilson Therapeutics with important achievements including its IPO on Nasdaq OMX in 2016, planning and execution of phase 3 development and the acquisition of Wilson Therapeutics by Alexion Pharmaceuticals in 2018. This is of particular importance to Ascelia’s lead drug candidate Mangoral® that has obtained Orphan Drug Designation from the FDA and is currently being prepared for its phase 3 clinical development”, says Magnus Corfitzen, Chief Executive Officer of Ascelia Pharma.
“I look forward to joining Ascelia Pharma and to contribute in its mission to improve the lives of patients living with cancer. Ascelia has two promising drug candidates, one in late-stage clinical development (Mangoral®) and one in earlier stage (Oncoral) and I’m strongly motivated to advance the development of these and bring them to patients”, says Carl Bjartmar.
For further information contact:
Magnus Corfitzen, CEO, +46 735 179 110
About Ascelia Pharma
Ascelia Pharma is a specialty pharmaceutical company dedicated to the development of novel medicines to improve the life expectancy and quality of life for people living with cancer. The company is located at Medeon Science Park in Malmö, Sweden in the middle of Medicon Valley, a leading European life science cluster. For more information, please visit http://www.ascelia.com